398 related articles for article (PubMed ID: 28710342)
41. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy.
Gupta AA; Pappo A; Saunders N; Hopyan S; Ferguson P; Wunder J; O'Sullivan B; Catton C; Greenberg M; Blackstein M
Cancer; 2010 Jul; 116(13):3189-94. PubMed ID: 20564643
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
Bacci G; Ferrari S; Bertoni F; Donati D; Bacchini P; Longhi A; Brach Del Prever A; Forni C; Rimondini S
J Clin Oncol; 2000 Feb; 18(4):885-92. PubMed ID: 10673532
[TBL] [Abstract][Full Text] [Related]
43. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
Yock TI; Krailo M; Fryer CJ; Donaldson SS; Miser JS; Chen Z; Bernstein M; Laurie F; Gebhardt MC; Grier HE; Tarbell NJ;
J Clin Oncol; 2006 Aug; 24(24):3838-43. PubMed ID: 16921035
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M
Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092
[TBL] [Abstract][Full Text] [Related]
45. Results of RS-99 protocol for childhood solid tumors.
Cai JY; Tang JY; Pan C; Xu M; Xue HL; Zhou M; Dong L; Ye QD; Jiang H; Shen SH; Chen J
World J Pediatr; 2010 Feb; 6(1):43-9. PubMed ID: 20143210
[TBL] [Abstract][Full Text] [Related]
46. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
[TBL] [Abstract][Full Text] [Related]
47. Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults.
Loschi S; Dufour C; Oberlin O; Goma G; Valteau-Couanet D; Gaspar N
Bone Marrow Transplant; 2015 Aug; 50(8):1083-8. PubMed ID: 26030048
[TBL] [Abstract][Full Text] [Related]
48. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
Verrill MW; Judson IR; Wiltshaw E; Thomas JM; Harmer CL; Fisher C
Ann Oncol; 1997 Nov; 8(11):1099-105. PubMed ID: 9426329
[TBL] [Abstract][Full Text] [Related]
49. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04.
Chin M; Yokoyama R; Sumi M; Okita H; Kawai A; Hosono A; Koga Y; Sano H; Watanabe H; Ozaki T; Mugishima H;
Pediatr Blood Cancer; 2020 May; 67(5):e28194. PubMed ID: 32077253
[TBL] [Abstract][Full Text] [Related]
50. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Juergens C; Weston C; Lewis I; Whelan J; Paulussen M; Oberlin O; Michon J; Zoubek A; Juergens H; Craft A
Pediatr Blood Cancer; 2006 Jul; 47(1):22-9. PubMed ID: 16572419
[TBL] [Abstract][Full Text] [Related]
51. Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031.
Cash T; Krailo MD; Buxton AB; Pawel BR; Healey JH; Binitie O; Marcus KJ; Grier HE; Grohar PJ; Reed DR; Weiss AR; Gorlick R; Janeway KA; DuBois SG; Womer RB
J Clin Oncol; 2023 Oct; 41(30):4724-4728. PubMed ID: 37651654
[No Abstract] [Full Text] [Related]
52. Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
DuBois SG; Grier HE
Nat Rev Clin Oncol; 2009 May; 6(5):251-3. PubMed ID: 19390548
[TBL] [Abstract][Full Text] [Related]
53. Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide.
Yoshihara H; Kamiya T; Hosoya Y; Hasegawa D; Ogawa C; Asanuma H; Mizuno R; Hosoya R; Manabe A
Pediatr Int; 2016 Aug; 58(8):766-9. PubMed ID: 27324740
[TBL] [Abstract][Full Text] [Related]
54. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
Sparber-Sauer M; Ferrari A; Kosztyla D; Ladenstein R; Cecchetto G; Kazanowska B; Scarzello G; Ljungman G; Milano GM; Niggli F; Alaggio R; Vokuhl C; Casanova M; Klingebiel T; Zin A; Koscielniak E; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29691. PubMed ID: 35441463
[TBL] [Abstract][Full Text] [Related]
55. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
Paulino AC; Nguyen TX; Mai WY; Teh BS; Wen BC
Pediatr Blood Cancer; 2007 Aug; 49(2):145-8. PubMed ID: 16732580
[TBL] [Abstract][Full Text] [Related]
56. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Brach del Prever A; Iantorno D; Forni C; Campanacci M
Minerva Pediatr; 1995 Nov; 47(11):457-69. PubMed ID: 8684341
[TBL] [Abstract][Full Text] [Related]
57. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
[TBL] [Abstract][Full Text] [Related]
58. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
59. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
Spunt SL; Francotte N; De Salvo GL; Chi YY; Zanetti I; Hayes-Jordan A; Kao SC; Orbach D; Brennan B; Weiss AR; van Noesel MM; Million L; Alaggio R; Parham DM; Kelsey A; Randall RL; McCarville MB; Bisogno G; Hawkins DS; Ferrari A
Eur J Cancer; 2019 May; 112():98-106. PubMed ID: 30954717
[TBL] [Abstract][Full Text] [Related]
60. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
